H Jadvar1, D L Johnson, G M Segall. 1. Nuclear Medicine Service, VA Palo Alto Health Care System, California 94304, USA.
Abstract
PURPOSE: To assess the effect of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) on the treatment of patients with cutaneous malignant melanoma. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 38 patients with newly diagnosed (n = 25) and recurrent (n = 13) cutaneous melanoma who were referred for evaluation with FDG PET imaging at our institution. We compared the PET findings with computed tomography (CT), which was available in 21 (55%) patients, and tabulated the changes in the diagnostic evaluation and therapeutic management that were prompted by PET during a follow-up period of 10 to 36 months. RESULTS: Compared with PET, the extent of disease was underestimated by CT in 5 (13%) patients. Planned surgical resection of metastases was canceled in two of these patients. In another patient, surveillance PET detected an unsuspected hypermetabolic abdominal mass that was noted on a subsequent CT to arise from the small bowel. The mass was found to be jejunal metastatic melanoma at the time of resection. Overall, PET influenced surgical management in 3 (8%) patients, but it did not affect the wait-and-watch strategy or decision to initiate immunotherapy in the others. CONCLUSIONS: FDG PET contributes important information not provided by CT and has a substantial effect on the clinical management of patients with malignant melanoma.
PURPOSE: To assess the effect of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) on the treatment of patients with cutaneous malignant melanoma. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 38 patients with newly diagnosed (n = 25) and recurrent (n = 13) cutaneous melanoma who were referred for evaluation with FDG PET imaging at our institution. We compared the PET findings with computed tomography (CT), which was available in 21 (55%) patients, and tabulated the changes in the diagnostic evaluation and therapeutic management that were prompted by PET during a follow-up period of 10 to 36 months. RESULTS: Compared with PET, the extent of disease was underestimated by CT in 5 (13%) patients. Planned surgical resection of metastases was canceled in two of these patients. In another patient, surveillance PET detected an unsuspected hypermetabolic abdominal mass that was noted on a subsequent CT to arise from the small bowel. The mass was found to be jejunal metastatic melanoma at the time of resection. Overall, PET influenced surgical management in 3 (8%) patients, but it did not affect the wait-and-watch strategy or decision to initiate immunotherapy in the others. CONCLUSIONS: FDG PET contributes important information not provided by CT and has a substantial effect on the clinical management of patients with malignant melanoma.
Authors: Marion T Harris; Salvatore U Berlangieri; Jonathan S Cebon; Ian D Davis; Andrew M Scott Journal: Mol Imaging Biol Date: 2005 Jul-Aug Impact factor: 3.488
Authors: Yan Xing; Yulia Bronstein; Merrick I Ross; Robert L Askew; Jeffrey E Lee; Jeffrey E Gershenwald; Richard Royal; Janice N Cormier Journal: J Natl Cancer Inst Date: 2010-11-16 Impact factor: 13.506
Authors: Steven E Finkelstein; Jorge A Carrasquillo; John M Hoffman; Barbara Galen; Peter Choyke; Donald E White; Steven A Rosenberg; Richard M Sherry Journal: Ann Surg Oncol Date: 2004-07-12 Impact factor: 5.344
Authors: Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams Journal: Cochrane Database Syst Rev Date: 2019-07-01